Project Database

Filters

Development of benchtop equipment for automated characterization of viruses and other biological nanoparticles

eurostars

This project will develop portable technology for rapid automatic characterization and identification of viruses and nano-sized biological particles, based on the participants’ unique expertise in miniaturized electron microscopy and image analysis and software development.

Composite-based Power Pylons

eurostars

ComPylon targets a unique market opportunity for design-driven redevelopment of overhead transmission lines (OHTLs), by developing and prototyping innovative, composite-based pylons that enable new, value-added designs and technical solutions. By disruptive designs enabled by non-conducting materials, the project will deliver smaller/more compact pylons and easier to erect, less costly and visually more appealing OTHL’s, thus constituting an alternative to the conventional lattice towers.

A simulation-based platform for personalized cerebral aneurysm therapy guidance with braided devices

eurostars

ANKloud will bring to the interventional neuroradiologists high precision tools for measuring anatomy, simulating and accurately positioning braided devices, guiding intracranial aneurysm treatment. The procedure planning and therapy guidance will be supported with proprietary computational tools that facilitate sizing and positioning of specific implants as well as allowing pre-treatment model simulations and physician training. Personalized models and devices will validate these tools.

Challenging African Swine Fever outbreaks with innovative VLP-based vaccines

eurostars

We will develop a safe and effective vaccine against African Swine Fever Virus (ASFV) to provide a solution to the spread of this lethal virus. Here, we will combine the power of big data analysis and Artificial Intelligence (AI) with our innovative virus-like particles (VLPs) vaccine platform to identify the right antigens and deliver proof of concept vaccine candidates for the circulating ASFV variant. This approach will pave the way to develop vaccines for other viruses in the future.

Coupling Test-based and Computer-based Models to Predict Critical NVH Issues in Automobiles

eurostars

We want to address the need for automotive OEMs to identify NVH (Noise, Vibration, and Harshness) issues early on during the vehicle development process in order to reduce its costs and time. We will deliver COUPLE, an innovative software application that accurately predicts the NVH characteristics of a vehicle even before complete physical prototypes are available. During the project, COUPLE will be validated in a real industrial environment by BMW and reach TRL 7.

VALIDATION OF PHOTONIC TECHNOLOGY FOR IN-ORBIT CUBE SATELLITE LASER COMMUNICATION

eurostars

The objective of the project is to create State-of-the-Art laser technology for in-space and space-to-ground optical communication links. We aim at building and testing a new transmitter/receiver link based on FYLA photonic technologies that will change from RF based communications, to Ultrafast/Ultra-wideband laser direct links. The challenge is to integrate it successfully onboard EnduroSat newest CubeSat platform. In addition, this link can be easily transferred to earth/earth applications.

Platform for Blue Cell isolation from autologous adipose tissue for effective regenerative therapy

eurostars

Blue4Therapy aims to deliver an innovative platform – BlueSORT - to enable the therapeutic use of a specific type of Adipose Derived Regenerative Cells (ADRCs) - Blue Cells - for Point-of-Care (PoC) treatment of chronic conditions with poor treatment options. BlueSORT will for the first time allow a cost-effective way to isolate autologous Blue Cells, enabling novel research and therapeutic avenues. RT has filed a patent for global use and exploitation rights of Blue Cells.

Tumor genome-based personalized anti-cancer mRNA vaccines off-the-shelf

eurostars

We will develop groundbreaking FraMix cancer vaccines that combine the expertise and unique technologies of Frame Therapeutics and eTheRNA Immunotherapies: (i) immunogenic frameshift neo-antigens, commonly expressed in tumors, enabling off-the-shelf vaccines, ii) a vaccination platform encompassing high quality anti-tumor T cell responses based on clinically validated TriMix mRNA and lipid nanoparticle delivery. The project delivers a vaccine for kidney cancer, ready for clinical development.